Comparison of Unenhanced and Gadolinium-Enhanced Imaging in Multiple Sclerosis: Is Contrast Needed for Routine Follow-Up MRI?

References

1. 1.↵
   1. Wallin MT,
   2. Culpepper WJ,
   3. Campbell JD, et al

   . The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology 2019;92:e1029–40 doi:10.1212/WNL.0000000000007035 pmid:30770430

   Abstract/FREE Full Text
2. 2.↵
   1. Lizan L,
   2. Comellas M,
   3. Paz S, et al

   . Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature. Patient Prefer Adherence 2014;8:1653–64 pmid:25525341

   PubMed
3. 3.↵
   1. Traboulsee A,
   2. Simon JH,
   3. Stone L, et al

   . Revised recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis. AJNR Am J Neuroradiol 2016;37:394–401 doi:10.3174/ajnr.A4539 pmid:26564433

   Abstract/FREE Full Text
4. 4.↵
   Consortium of. MS Centers MRI Protocol for the Diagnosis and Follow-up of MS and Clinical Guidelines for the Diagnosis and Follow-Up OF MS. 2018 revised guidelines. Februrary 2018. https://cdn.ymaws.com/mscare.site-ym.com/resource/collection/9C5F19B9-3489-48B0-A54B-623A1ECEE07B/2018MRIGuidelines_booklet_with_final_changes_0522.pdf. Accessed on May 9, 2019.
5. 5.↵
   1. Rudick RA,
   2. Lee JC,
   3. Simon J, et al

   . Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol 2006;60:236–42 doi:10.1002/ana.20883 pmid:16786526

   CrossRefPubMedWeb of Science
6. 6.
   1. Sormani MP,
   2. Bonzano L,
   3. Roccatagliata L, et al

   . Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009;65:268–75 doi:10.1002/ana.21606 pmid:19334061

   CrossRefPubMed
7. 7.↵
   1. Prosperini L,
   2. Gallo V,
   3. Petsas N, et al

   . One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 2009;16:1202–09 doi:10.1111/j.1468-1331.2009.02708.x pmid:19538207

   CrossRefPubMed
8. 8.↵
   1. Wattjes MP,
   2. Barkhof F.

   Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr Opin Neurol 2014;27:260–70 doi:10.1097/WCO.0000000000000099 pmid:24739400

   CrossRefPubMed
9. 9.↵
   1. Filippi M,
   2. Rovaris M,
   3. Bastianello S, et al

   . A comparison of the sensitivity of monthly unenhanced and enhanced MRI techniques in detecting new multiple sclerosis lesions. J Neurol 1999;246:97–106 doi:10.1007/s004150050315 pmid:10195404

   CrossRefPubMed
10. 10.↵
    1. Eichinger P,
    2. Schon S,
    3. Pongratz V, et al

    . Accuracy of unenhanced MRI in the detection of new brain lesions in multiple sclerosis. Radiology 2019;291:429–35 doi:10.1148/radiol.2019181568 pmid:30860448

    CrossRefPubMed
11. 11.↵
    1. Mattay RR,
    2. Davtyan K,
    3. Bilello M, et al

    . Do all patients with multiple sclerosis benefit from the use of contrast on serial follow-up MR imaging? A retrospective analysis. AJNR Am J Neuroradiol 2018;39:2001–06 doi:10.3174/ajnr.A5828 pmid:30287455

    Abstract/FREE Full Text
12. 12.
    1. Saindane AM.

    Is Gadolinium-based contrast material needed for MRI follow-up of multiple sclerosis? Radiology 2019;291:436–37 doi:10.1148/radiol.2019190319 pmid:30860449

    CrossRefPubMed
13. 13.↵
    1. Karimian-Jazi K,
    2. Wildemann B,
    3. Diem R, et al

    . Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI. Neurol Neuroimmunol Neuroinflamm 2018;5:e480 doi:10.1212/NXI.0000000000000480 pmid:30038948

    Abstract/FREE Full Text
14. 14.↵
    1. Guo BJ,
    2. Yang ZL,
    3. Zhang LJ.

    Gadolinium deposition in brain: current scientific evidence and future perspectives. Front Mol Neurosci 2018;11:335 doi:10.3389/fnmol.2018.00335 pmid:30294259

    CrossRefPubMed
15. 15.
    1. Kang H,
    2. Hii M,
    3. Le M, et al

    . Gadolinium deposition in deep brain structures: relationship with dose and ionization of linear gadolinium-based contrast agents. AJNR Am J Neuroradiol 2018;39:1597–1603 doi:10.3174/ajnr.A5751 pmid:30139752

    Abstract/FREE Full Text
16. 16.↵
    1. Olchowy C,
    2. Cebulski K,
    3. Łasecki M, et al

    . The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity: a systematic review. PLoS One 2017;12:e0171704 doi:10.1371/journal.pone.0171704 pmid:28187173

    CrossRefPubMed
17. 17.↵
    1. Krause I,
    2. Kern S,
    3. Horntrich A, et al

    . Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors. Mult Scler 2013;19:1792–99 doi:10.1177/1352458513485655 pmid:23635910

    CrossRefPubMed
18. 18.↵
    1. Palmer AJ,
    2. van der Mei I,
    3. Taylor BV, et al

    . Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: evidence from Australia. Mult Scler 2019 Feb 26. [Epub ahead of print] doi:10.1177/1352458519831213 pmid:30806569

    CrossRefPubMed
19. 19.↵
    1. Mamlouk MD,
    2. Chang PC,
    3. Saket RR.

    Contextual radiology reporting: a new approach to neuroradiology structured templates. AJNR Am J Neuroradiol 2018;39:1406–14 doi:10.1177/1352458519831213 pmid:29903922

    Abstract/FREE Full Text
20. 20.↵
    1. Kermode AG,
    2. Thompson AJ,
    3. Tofts P, et al

    . Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenetic and clinical implications. Brain 1990;113:1477–89 doi:10.1093/brain/113.5.1477 pmid:2245307

    CrossRefPubMed
21. 21.↵
    1. Harris JO,
    2. Frank JA,
    3. Patronas N, et al

    . Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991;29:548–55 doi:10.1002/ana.410290515 pmid:1859184

    CrossRefPubMedWeb of Science